Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterates a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and maintains a $31 price target.
April 11, 2024 | 8:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reaffirmed a Buy rating on Nurix Therapeutics, with a price target of $31, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $31 price target by a reputable analyst like Gil Blum from Needham suggests a strong conviction in the stock's potential for growth. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100